WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced ...
Hosted on MSN
Climb Bio Appoints New CFO Susan Altschuller
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Climb Bio ( (CLYM)) has issued an update.
Climb Bio appointed Susan Altschuller chief financial officer as the clinical-stage biotechnology company pushes ahead with the development of two flagship therapeutics for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback